Zhejiang Yatai Pharmaceutical Co Ltd is a China-based company mainly engaged in software research and development business and Internet sharing economy platform construction and operation business. The Company is mainly engaged in software development and system integration business, and provides technical services. The Company's products are mainly used in artificial intelligence, data elements, government affairs, public security, urban governance, environmental protection, politics and law, water conservancy and other industries.

Employees

529

Sector

Pharmaceuticals

More about the company

Quotes

Date	Price	Change	Volume
15/05/26	6.390 ¥	-1.39%	15,967,980
14/05/26	6.480 ¥	-2.70%	21,752,490
13/05/26	6.660 ¥	+1.68%	26,812,850
12/05/26	6.550 ¥	-3.96%	37,291,740
11/05/26	6.820 ¥	+2.10%	31,314,020

End-of-day quote Shenzhen S.E.

More quotes

Income Statement and Estimates

More financial data

End-of-day quote Shenzhen S.E. Other stock markets 15/05/2026			5-day change	1st Jan Change
6.390 ^CNY	-1.39%		-4.34%	-12.59%

04-24	Zhejiang Yatai Pharmaceutical Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2026	CI
03-05	Yatai Pharma's Subsidiary to Set Up Joint Venture	MT

Capitalization	4.76B 700M 602M 551M 526M 964M 67.17B 979M 6.61B 2.56B 31.89B 2.63B 2.57B 111B	P/E ratio 2024	61x	P/E ratio 2025	56.2x
Enterprise value	4.15B 609M 524M 479M 457M 838M 58.45B 852M 5.75B 2.23B 27.75B 2.29B 2.24B 96.67B	EV / Sales 2024	4.35x	EV / Sales 2025	15x
Free-Float	75.06%	Yield 2024 *	-	Yield 2025	-

04-24	Zhejiang Yatai Pharmaceutical Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2026	CI
03-05	Yatai Pharma's Subsidiary to Set Up Joint Venture	MT
02-09	Zhejiang Yatai Pharmaceutical Co., Ltd. Approves Board Appointments	CI
01-06	Zhejiang Xinghao Holding Partnership Enterprise (Limited Partnership) and Zhejiang Xingchen Equity Investment Partnership Enterprise (Limited Partnership) completed the acquisition of 14.61% stake in Zhejiang Yatai Pharmaceutical Co., Ltd. from Ningbo Fubang Holding Group Limited and Shanghai Hangui Investment Management Co., Ltd.	CI
28/10/25	Zhejiang Yatai Pharmaceutical Co., Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2025	CI
13/10/25	Zhejiang Yatai Pharmaceutical to raise funds, share trade to resume	RE
12/10/25	Zhejiang Yatai Pharmaceutical Co., Ltd. announced that it expects to receive CNY 699.999998 million in funding from Zhejiang Xinghao Holding Partnership Enterprise (Limited Partnership)	CI
12/10/25	Zhejiang Xinghao Holding Partnership Enterprise (Limited Partnership) and Zhejiang Xingchen Equity Investment Partnership Enterprise (Limited Partnership) entered into agreement to acquire 14.61% stake in Zhejiang Yatai Pharmaceutical Co., Ltd. from Ningbo Fubang Holding Group Limited and Shanghai Hangui Investment Management Co., Ltd. for approximately CNY 900 million.	CI
29/09/25	Yatai Pharmaceutical May Change Control Amid Parent's Plan	MT
28/09/25	Trading in Zhejiang Yatai Pharmaceutical's shares to halt	RE
29/08/25	Zhejiang Yatai Pharmaceutical Co., Ltd. Reports Earnings Results for the Half Year Ended June 30, 2025	CI
11/07/25	Zhejiang Yatai Pharmaceutical's Fluid Buildup Tablets Passes China Consistency Evaluation	MT
24/06/25	Zhejiang Zhongqingda Construction Industry Co., Ltd. completed the acquisition of Shaoxing Xingya Pharmaceutical Co., Ltd. from Zhejiang Yatai Pharmaceutical Co., Ltd..	CI

1 day	-1.39%
1 week	-4.34%
Current month	-5.05%
1 month	-16.91%
3 months	-9.23%
6 months	-27.30%
Current year	-12.59%

Zhejiang Yatai Pharmaceutical Co., Ltd. Share Price

Equities

002370

CNE100000MM5

Pharmaceuticals

Valuation: Zhejiang Yatai Pharmaceutical Co., Ltd.

Chart: Zhejiang Yatai Pharmaceutical Co., Ltd.

Latest news : Zhejiang Yatai Pharmaceutical Co., Ltd.

Quotes and Performance

Course Extremes

Managers and Directors: Zhejiang Yatai Pharmaceutical Co., Ltd.

Other Pharmaceuticals

Financials

Company Profile

Quotes

Income Statement and Estimates

1 week	6.35	6.82
1 month	6.35	7.62
Current year	5.8	8.22
1 year	3.34	9.41
3 years	2.21	9.41
5 years	2.21	10.2
10 years	2.21	22.15

Manager	Title	Age	Since
Jian Wei Cen CEO	Chief Executive Officer	54	06/02/2024
Jing Yang Xu DFI	Director of Finance/CFO	45	14/04/2022
Wei Huang SAM	Sales & Marketing	46	14/04/2022

Director	Title	Age	Since
Hua Ying Zhou BRD	Director/Board Member	57	14/04/2022
Min Tu BRD	Director/Board Member	59	24/08/2022
Ling Jie Song CHM	Chairman	37	14/04/2022

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5d. change	1-year change	3-years change	Capi.($)
ZHEJIANG YATAI PHARMACEUTICAL CO., LTD.	-1.39%	-4.34%	+87.94%	+48.95%	700M
ELI LILLY AND COMPANY	-0.00%	+5.95%	+32.68%	+130.14%	896B
JOHNSON & JOHNSON	-1.77%	+2.44%	+49.81%	+42.28%	546B
ABBVIE INC.	-0.18%	+4.39%	+14.33%	+46.83%	372B
ROCHE HOLDING AG	+0.88%	+2.38%	+24.30%	+14.35%	328B
NOVARTIS AG	-0.10%	+2.93%	+27.56%	+26.14%	283B
ASTRAZENECA PLC	-0.79%	+2.16%	+31.97%	+12.94%	282B
MERCK & CO., INC.	-1.79%	0.00%	+46.44%	-4.05%	275B
NOVO NORDISK A/S	+0.91%	+3.07%	-29.86%	-47.76%	206B
AMGEN INC.	-2.22%	-1.62%	+19.79%	+43.19%	176B
Average	-0.65%	+1.57%	+30.50%	+31.30%	336.4B
Weighted average by Cap.	-0.50%	+3.38%	+28.75%	+50.39%

	2024	2025
Net sales	405M 59.54M 51.23M 46.84M 44.69M 81.93M 5.71B 83.29M 562M 217M 2.71B 223M 219M 9.45B	323M 47.48M 40.86M 37.36M 35.64M 65.34M 4.56B 66.42M 448M 173M 2.16B 178M 174M 7.53B
Net income	34.24M 5.03M 4.33M 3.96M 3.78M 6.92M 483M 7.04M 47.49M 18.38M 229M 18.88M 18.48M 798M	96.31M 14.15M 12.18M 11.13M 10.62M 19.47M 1.36B 19.8M 134M 51.69M 645M 53.11M 51.97M 2.25B
Net Debt	-412M -60.55M -52.11M -47.64M -45.46M -83.33M -5.81B -84.71M -572M -221M -2.76B -227M -222M -9.61B	-619M -90.92M -78.23M -71.53M -68.25M -125M -8.72B -127M -858M -332M -4.14B -341M -334M -14.43B